



## **Assessment of Sexual Functions among Male with Substance Use Disorders**

**Ahmed Osama Tolba<sup>1\*</sup>, Mohammad Abd El Hakim Selem<sup>1</sup>,  
Maged Mostafa Ragab<sup>1</sup>, Ahmed Abd El Rahman Mubarak<sup>1</sup>  
and Adel Abd El Kerem Badawy<sup>1</sup>**

<sup>1</sup>Neuropsychiatry Department, Faculty of Medicine - Tanta University, Tanta, Egypt.

### **Authors' contributions**

*This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.*

### **Article Information**

DOI: 10.9734/JAMMR/2021/v33i1731028

#### Editor(s):

(1) Dr. Rui Yu, The University of North Carolina at Chapel Hill, USA.

#### Reviewers:

(1) Usama bin zubair, FUMC ,Pakistan.

(2) MOHAMAD HASHIM BIN OTHMAN, Universiti Sains Malaysia, Malaysia.

(3) SITI RABA'AH HAMZAH, Universiti Putra Malaysia, Malaysia.

Complete Peer review History: <https://www.sdiarticle4.com/review-history/71947>

**Original Research Article**

**Received 15 May 2021**  
**Accepted 29 July 2021**  
**Published 30 July 2021**

### **ABSTRACT**

**Background:** Recent epidemiological and clinical studies confirmed the presence of a strong association between substance use disorders and sexual dysfunctions. Studies have demonstrated that prevalence of sexual dysfunctions among addict was about 30 %the most common problem among male substance abuse patients were Erectile Dysfunction (ED) and delayed ejaculation  
**Methods:** This cohort comparative study was conducted on of 376 males aged between 18 – 50 years who were substance abusers including tramadol, cannabis and poly substance related and addictive disorders. All participants were subjected to psychiatric interview which was done using SCID-5-CV structured clinical interview for DSM-5 disorders. Psychometric, biochemical, medical and drug history evaluations were also performed.  
**Results:** Our results show comparison between four groups (opiates-cannabis-poly substance abuse and control group according to severity of drug abuse, psychiatric evaluation and according to sexual functions. There were statistically significant differences between groups in sociodemographic data mainly in occupational and educational history. There also were statistically significant differences between groups in terms of drug use, psychiatric assessment, assessment of sexual activity, hormonal assessment of the studied population and quality of life assessment.

\*Corresponding author: E-mail: [Ahmed\\_psycho1987@yahoo.com](mailto:Ahmed_psycho1987@yahoo.com);

**Conclusions:** Long term drug use has a statistically significant negative effect on all domains of male sexual functions. Also average daily dose and severity of addiction are significantly correlated to sexual dysfunctions in patients with tramadol abuse. This is done through an alteration in sex hormone and alters feedback regulations of the pituitary on the hypothalamus.

*Keywords:* Sexual functions; tramadol; opiates; cannabis.

## 1. INTRODUCTION

Substance use disorders (SUDs) are a global health problem which present in a variety of clinical settings. Substance use may complicate an underlying medical or psychiatric disorder and can also lead to medical or psychological morbidity in its own right [1].

In an Egyptian study by Kamel et al., 1995 cannabis was the most widely used drug followed by opioids and in a more recent study by El-Sawy and Abd Elhay it was found that adolescents (exposed to trauma) were more likely to use tramadol, followed by cannabis and benzodiazepines [2,3]. Psychosexual disorders are dysfunctions of the sexual response cycle that cause impaired sexual performance and distress to affected patients and their partners. These disorders can affect any phase of the sexual response cycle. The commonest sexual disorders seen in male patients are premature ejaculation and erectile dysfunction [4].

At the turn of the twenty-first century, the situation has changed dramatically. The recognition of a high prevalence of sexual disorders in the community, coupled with the rapid expansion of research on pharmacologic treatments for sexual dysfunctions, has resulted in the development of numerous new measures of sexual functioning [5].

In 2016, the United States Food & Drug Administration (FDA) issued a warning regarding severe safety issues associated with opioid pain medications as long-term use of opioids may be associated with decreased sex hormone levels and symptoms such as reduced interest in sex, impotence, or infertility [6].

Prevalence of sexual dysfunctions among addict was about 30% the most common problem among male substance abuse patients was ED and delayed ejaculation [7].

The aim of this study was to assess impact of various substance abuse on sexual functions.

## 2. PATIENTS AND METHODS

This cohort comparative study was conducted on of 376 males aged between 18 – 50 years who were substance abusers including tramadol, cannabis and poly substance related and addictive disorders. The study recruited participants who met the criteria of DSM- 5 for substance related disorders and attended either the outpatients and inpatient services of Neuropsychiatry Department and Center of Psychiatry, Neurology, and Neurosurgery hospital at Tanta University or Andrology unite of Urology department at Tanta University Hospital. After approval from Tanta University Institutional Review Board, a written informed consent was obtained from each participant.

Exclusion criteria were patients who had severe neurological disorders e.g. Parkinsonism, paraplegia as these conditions affect sexual function. Patients with history of medical conditions e.g., diabetes, hypertensive as these conditions may affect sexual performance. Patients who had severe psychiatric illness e.g., schizophrenia or bipolar disorders. Patients receiving psychiatric drugs which interfere with sexual functions such as psychotropic drugs SSRIS and antihypertensive.

The participants were allocated to one of four groups. Group 1: tramadol related addictive disorders (n= 94). Group 2: cannabis related addictive disorders (n= 94). Group 3: poly substance related addictive disorders (n= 94). Group 4: control group (n= 94).

### 2.1 Psychiatric Evaluation

All participants were subjected to psychiatric interview which was done using SCID-5-CV structured clinical interview for DSM-5 disorders, the clinical version for diagnosis of substance related disorders. Assessment of addiction severity was performed using Arabic version of addiction severity index. Collection of sociodemographic data of the studied populations which include age, occupation, residence, education, smoking and smoking

index. Complete evaluation of family characteristics among participants. Urine test for detection of the substance of use related disorders.

Psychometric evaluation was done to evaluate presence of comorbidity of anxiety or depressive symptoms by hospital anxiety and depression scale Arabic version.

Medical and drug history of the patient were collected to exclude any other causes of sexual dysfunctions. The assessment of sexual functions was done using complete sexual history. Psychometric assessment including assessment for all stages of sexual cycle was done using Arizona sexual experience scale, Arabic version of international index of erectile dysfunction and men health questioner.

Biochemical evaluation was done through hormonal assessment. Urological evaluation was done using urological examination, Penile doppler to exclude any possible organic causes. Quality of Life Enjoyment and Satisfaction Questionnaire (short form) was used for the assessment of quality of life.

## 2.2 Statistical Analysis

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS). The Fisher exact test was used to compare categorical variables. The continuous variables were analyzed using the independent sample t test. All P values were 2-tailed, and statistical significance was set at  $P > 0.05$ .

## 3. RESULTS

### 3.1 The Results of the Current Study Included

The difference between the four groups was significant as regards their marital status and age of onset of substance use while no significant difference regarding to age Table 1.

Both tramadol and cannabis related disorders use these substances for sexual purposes more than the group of polysubstance related disorders ( $\chi^2 = 44.95$ ,  $p = 0.001$ ). Previous treatment in opiates (tramadol) group show that 52 (55.3%) had previous treatment while in Cannabis group it show that 30 (31.9%) had

previous treatment and in Poly substance group it show that 74 (78.7%) had previous treatment. There were statistically significant differences between groups Table 2.

There were a significantly higher comorbidity of anxiety and depression among poly substance abuse group compared to mono substance use groups Table 3.

There were statistically significant differences between groups according to the mean age of starting sex, ever had sex, source of sexual knowledge and sexual activity and masturbation during last three-months before marriage Table 4.

There were statistically significant differences between groups according to erectile functions, sexual satisfaction, orgasmic functions, sexual desire, general satisfaction and a total evaluation score Table 5.

There were statistically significant differences between groups according to total testosterone, FSH, LH, Prolactin and estrogen levels in addition to Quality of Life assessment score Table 6.

## 4. DISCUSSION

The systematic evaluation in this study shows substantial and symmetrical overlap between substance abuse and sexual dysfunctions which have a direct impact on all sexual function domains lead to impairment of quality of life and worsening of the prognosis.

Patient above 50 years were excluded in the current study, this helps avoiding as much as possible the effect of age on sexual functions.

Other studies put comparable age restrictions for the same purpose, El-Hadid & El-Gilani (2014) for example didn't state a maximum age for inclusion, however there was no subjects in their sample above 49 years [8].

Non workers percentage was higher among poly substance use group than mono substance group. This is because non-employment was one of the biggest indicators associated with substance abuse. That is why non-employment was more common among poly substance group than mono substance group [9].

**Table 1. Age and marital status of the studied population**

		<b>Tramadol group N=94</b>	<b>related Cannabis group N=94</b>	<b>related Polysubstance group N=94</b>	<b>related Control group N=94</b>	<b>χ<sup>2</sup></b>	<b>P</b>
Age		36.56±7.355	34.85±4.056	38.83±4.701	34.28±8.420	31.499	0.138
Marital status	Single	15 (16%)	20 (21.3%)	7 (7.4%)	-	41.805	<0.001*
	divorced	16 (17%)	3 (3.2%)	17 (17%)	-		
	widow	3 (3.2%)	1 (1.1%)	2 (2.1%)	-		
	married	30 (31.9%)	45 (47.9%)	29 (30.9%)	-		
	Separated (troublesome)	30 (31.9%)	25 (26.6%)	39 (41.5%)	-		
Age of onset of substance use		27.87±8.108	17.38±2.878	29.61±2.334	-	155.206	<0.001*
TUKEY'S Test							
Age of Onset		Tramadol & Cannabis		Tramadol & Poly		Cannabis & Poly	
		<0.001*		0.056		<0.001*	

\*Significant (P≤0.05)

**Table 2. Sexual and non-sexual motives for substance use and history of previous treatment trials among studied groups**

		<b>Tramadol related group N=94</b>	<b>Cannabis Related group N=94</b>	<b>Polysubstance related group N=94</b>	<b>χ<sup>2</sup></b>	<b>p</b>
Sexual motives	Yes	14 (14.8%)	21(22.3%)	54 (57.4)	44.95	0.001*
	No	80 (85.2%)	73 (77.7)	40 (42.6)		
History of previous treatment trials	Yes	42 (44.7%)	64 (68.1%)	20 (21.3%)	41.663	<0.001*
	No	52 (55.3%)	30 (31.9%)	74 (78.7%)		

\*Significant (P≤0.05)

**Table 3. Depression and anxiety assessment by Hospital Anxiety and Depression scale**

<b>Variable</b>	<b>Tramadol related group N=94</b>	<b>Cannabis related group N=94</b>	<b>Polysubstance related group N=94</b>	<b>Control group N=94</b>	<b>P value</b>
No	52 (55.3%)	61 (64.9%)	35 (37.2%)	84 (89.4%)	<0.001*
Yes	42 (44.7%)	33 (35.1%)	59 (62.8%)	10 (10.6%)	

\*Significant (P≤0.05)

**Table 4. Comparison between studied groups according to characters of sexual behaviour (sexual history)**

<b>Variable</b>	<b>Opiates (tramadol) n=94</b>		<b>Cannabis n=94</b>		<b>Poly substance n=94</b>		<b>Control n=94</b>		<b>F χ<sup>2</sup></b>	<b>P value</b>
	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>		
Mean age of starting sex	20.96±0.747		15.95±0.575		14.99±0.374		22.04±0.386		1082.075	<0.001*
Ever had sex										
No	28	29.8	41	43.6	13	13.8	27	28.7	20.297	<0.001*
Yes	66	70.2	53	56.4	81	86.2	67	71.3		
Source of sexual knowledge										
Porn movies	48	51.1	51	54.3	62	66.0	55	58.5	29.454	0.001*
Porn picture	26	27.7	27	28.7	20	21.3	14	14.9		
Sexual relationship	13	13.8	11	11.7	8	8.5	5	5.3		
Family information	7	7.4	5	5.3	4	4.3	20	21.3		
Sexual activity during last three month										
With wives	42	44.7	38	40.4	25	26.6	67	71.3	43.579	<0.001*
Masturbation	31	33.0	27	28.7	44	46.8	17	18.1		
Masturbation before marriage										
Once / week	39	41.5	43	45.7	33	35.1	51	54.3	28.652	0.001*
Daily	15	16.0	13	13.8	31	33.0	10	10.6		
More than one time/day	22	23.4	14	14.9	20	21.3	13	13.8		
Infrequent	18	19.1	24	25.5	10	10.6	20	21.3		
TUKEY'S Test										
Age of Starting sex	Tramadol & Cannabis		Tramadol & Poly		Tramadol & Control		Cannabis & Poly		Cannabis & Control	Poly & Control
	<0.001*		<0.001*		<0.001*		<0.001*		<0.001*	<0.001*

\*Significant (P≤0.05)

**Table 5. Psychometric evaluation of sexual activity with international index of erectile function (IEEF)**

Variable	Tramadol related group N=94	Cannabis related group N=94	Polysubstance related group N=94	Control group N=94	P value	
Erectile function	9.00±0.207	16.02±0.463	5.99±0.647	26.99±0.740	<0.001*	
Sexual satisfaction	3.46±0.501	7.88±0.323	2.77±0.426	9.88±0.323	<0.001*	
Orgasmic function	3.05±0.226	6.87±0.335	2.93±0.421	10.31±0.529	<0.001*	
Sexual desire	4.06±0.246	6.48±0.502	3.94±0.564	7.18±0.718	<0.001*	
General satisfaction	3.80±0.649	7.13±0.335	3.62±0.893	8.18±0.816	<0.001*	
Total score	23.37±0.892	44.38±0.940	19.23±1.402	62.54±1.373	<0.001*	
TUKEY'S Test						
	Tramadol & Cannabis	Tramadol& Poly	Tramadol& Control	Cannabis & Poly	Cannabis & Control	Poly & Control
Erectile function	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
Sexual Satisfaction	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
Orgasmic function	<0.001*	0.119	<0.001*	<0.001*	<0.001*	<0.001*
Sexual Desire Score	<0.001*	0.360	<0.001*	<0.001*	<0.001*	<0.001*
General Satisfaction Score	<0.001*	0.297	<0.001*	<0.001*	<0.001*	<0.001*
Total Score	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*

\*Significant (P≤0.05)

**Table 6. Comparison between studied groups according to hormonal essay among male addict patients and quality of life assessment**

Variable	Tramadol related group N=94	Cannabis related group N=94	Polysubstance related group N=94	Control n=94	F	P value
Total Testosterone	2.47±0.850	3.49±0.629	1.19±0.494	4.52±1.834	161.187	<0.001*
F S H	3.84±1.030	5.52±0.701	1.69±0.503	7.22±3.228	171.985	<0.001*
L H	4.08±0.845	4.99±0.814	1.80±0.616	5.21±2.291	130.303	<0.001*
Prolactin	15.12±1.671	11.22±1.903	26.76±3.681	9.40±3.319	738.115	<0.001*
Estrogen	44.37±5.753	34.20±2.758	52.62±4.866	29.80±5.278	429.038	<0.001*
Quality of life score	34.26±5.584	44.79±5.611	25.20±3.198	57.87±4.537	795.364	<0.001*
TUKEY'S Test						
	Tramadol & Cannabis	Tramadol & Poly	Tramadol & Control	Cannabis & Poly	Cannabis & Control	Poly & Control
Testosterone	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
FSH	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
LH	<0.001*	<0.001*	<0.001*	<0.001*	0.637	<0.001*
Prolactin	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
Estrogen	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
Quality of life score	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*

\*Significant (P≤0.05)

Also no obvious difference between substance abuse due to difference in places although some scholars believe that addiction is the result of urban development, [10]. Also another scholars believe that public participation plays an important role in reducing this problem [11,12].

Drug addictions can affect a marriage in different ways ,time spent away from the marriage, as an addict dedicates more and more time to procuring and consuming their substance of choice this lead to increased emotional distance between partners and higher levels of stress in the relationship [13].

There are numerous factors associated with the support from patients wives such as occupation and education .there are positive correlation between the level of wife education and occupation with her attitude to her husband problem and sharing in supply the required support for her husband .

It was concluded that wife attitude to treatment and her husband was negative among poly substance than mono substance use group .this is attributed to level of wife education and occupation .this reflected on compliance of treatment.

In the current study, age of cannabis use was early than other groups. This in agreement with other studies. Rotermann, reported that one in five Canadian youth between the ages of 15–19 report having used cannabis in the last year [14]. In the Egyptian culture Cannabis is easy accessible and is the most common substance of abuse among adolescents.

Studies on sex-related drinking motives suggest that individuals abuse drugs for various sex-related reasons, including enhancement of sex, to increase sexual risk-taking, and to decrease anxiety about sexual activity.

Banks & Zapolski, ; Celio et al.,; Messman-Moore et al. and Nash et al., reporting more sex-related abuse motives have greater levels of heavy and problem abuse [15-18]. Drugs are also often used in conjunction with sex (sometimes termed “Chem Sex”) [19].

There is great difficulty in management of substance abuse as our findings suggest that substance abuse treatment services require more integrated, individualized, comprehensive, and longer-term approaches to care. Specifically

limited housing and treatment options. Because housing is considered critical for sober living, inadequate housing resources impact lengths of stay [20].

Research also documents a reverse gateway effect, whereby those who smoke marijuana in early young adulthood are more likely to initiate tobacco use and to have a greater likelihood of developing nicotine dependence than their non-smoking peers [21-23].

Those who go on to have problems with the use of illicit drugs, including but not limited to marijuana, are more likely to be heavy smokers, to be nicotine dependent, and to experience greater difficulty with quitting smoking [24].

There is great comorbidity between substance abuse and psychiatric disorders especially anxiety and depressive symptoms which worsen their sexual performance which lead to more depressive and anxiety symptoms which has a direct impact on quality of life.

Several studies have demonstrated that, of the various negative effects, prolonged use of drugs leads to impairment of sexual function and, with time, may lead to onset of sexual disorders [25].

According to La Pera *et al.*, 34.8% declared that a sexual disorder had influenced their decision to start taking illegal drugs. This percentage is statistically higher in those presenting a sexual disorder prior to first drug use .Furthermore, this percentage tends to increase with the increase in sexual disorders [25].

Indeed, of the subjects presenting only one sexual disorder, this percentage is 33.3%, while in those with two sexual disorders, that is, PE(premature ejaculation) and ED(erectile dysfunctions), this percentage reaches 43%. On the other hand, when three sexual disorders are present, that is, PE and ED, LSD(lack of sexual desire) this percentage rises to 75% [25].

In this study, the use of opioids is associated with some high-risk sexual behaviours and a reported early age of sexual initiation in Egyptian adult drug users. Participants in the study reported high rates of sexual activity over the previous 3 months, exchange of sex for drugs or money, rates of risky sexual behaviours were observed, particularly in poly substance users. The data reported by the study sample are consistent with those obtained in previous research. These high

rates of sexual behaviours may be due to impulsivity and lack of self-control which was associated with substance use disorders [26,27].

However, the age of sexual initiation in our sample is earlier when compared with that of the normal Egyptian population (16 years) and of street children (15 years) [28,29].

Male addicts involve in frequent masturbation before marriage even after it with pleasurable seeking activities patients seek for [30].

Effect of opiates (tramadol) on sexual functions is due to its effect on sex hormones, Oxidative stress has been proposed to be related to erectile dysfunction (ED),serotonergic activity and its negative effect on opioid receptors [31].

According to orgasmic function There was a statistically significant difference between the three groups as orgasmic function in opiates (tramadol) group was with a mean value of  $3.05\pm 0.226$  while in Cannabis group it was with a mean value of  $6.87\pm 0.335$  and in Poly substance group it was with a mean value of  $2.93\pm 0.421$  finally in control group it was with a mean value of  $10.31\pm 0.529$ . This in agreement with other previous studies (Zhang et al. and Abdelazim et al.,) [32,33].

Our study found a statistically significant negative correlation between daily dose of tramadol and both erectile function and sexual desire. This is in consistent with Cushman (1973) who found a significant inverse correlation between opiates dose and serum testosterone level and hence sexual functions [34].

However, the results of this study is in contrast with Al-Gommer et al., and Abd El-Qader who failed to demonstrate any significant relationship between dose of heroin or tramadol and any of sexual functions or sex hormone levels. This can be explained by the relatively smaller number of subjects and lower average of daily dose of tramadol in their study than ours [35,36].

The research of Palha and Esteves; Babakhanian, [37,38], who studied sexual dysfunction among 101 heroin addicts, found that 60% of them had problems achieving orgasm. They also found that 75% of men in their study complained of low libido, 71% reported altered sexual arousal, and 72% had reduced sexual satisfaction.

Abel [39] reported that a small amount of cannabis can enhance sexual activity but larger quantities can suppress sexual motivation. Similar dose-dependent effects were confirmed by some other clinical studies Koff; Chopra [40] and Jandu [41], however, in a recent study, no association was found between frequency of cannabis use and sexual desire [42].

Thereafter, in a clinical study, erectile dysfunction was found twice more common in daily cannabis users than the control group. This finding was supported by another study which showed that cannabis consumption can be the cause of erectile dysfunction through its effect on endothelial function [43].

Similarly, Smith et al. reported that there is not an association between the frequency of cannabis use and erectile dysfunction in a computer-assisted telephone survey, this is may be due to lack of psychometric evaluation for every sexual domain instead of global evaluation.

Regarding the orgasmic function, the first prominent study of the literature was conducted. They reported that 68% of male cannabis users expressed that cannabis use increased the quality of orgasm but did not have a positive effect on quantity of orgasm [44].

Meanwhile, Kumsar et al. reported that there was not a significant difference between cannabis users and healthy controls in terms of sexual intercourse and overall satisfaction.

Another parameter taken into consideration during the evaluation of sexual function was sexual satisfaction. There were only limited number of studies providing data about the association of cannabis use and sexual satisfaction [45].

After abstinence from substances the hormonal levels of the three groups significantly changed, testosterone, FSH and LH became significantly higher than the basic levels and both prolactin and estrogen lowered in all groups.

Mikhail study has shown a direct interference of tramadol consumption with pituitary release of LH and FSH which could interfere with the menstrual cycle in women by blunting of the normal pulsatile release of LH and direct negative effects on the testes of males resulting in testosterone decrease and a reduction in testicular interstitial fluids which lead to decrease



in sexual drive as well as sustenance of erection [46].

In general, it is believed that marijuana consumption decreases LH levels [47,48].

Cannabinoid receptors are closely related to neurons in the hypothalamus and GnRH release has been shown to be inhibited in males through interaction with GABA and other systems [49].

There were statistically significant differences between groups as quality of life affected with prolonged and multiple substance abuse with disastrous effect on sexual functions and comorbidity with anxiety and depression [50].

## 5. CONCLUSIONS

Long term drug abuse has a statistically significant negative effect on all domains of male sexual functions. Also, average daily dose and severity of addiction are significantly correlated to sexual dysfunctions in patients with tramadol abuse. This is done through an alteration in sex hormone and alters feedback regulations of the pituitary on the hypothalamus.

## CONSENT AND ETHICAL APPROVAL

The study recruited participants who met the criteria of DSM- 5 for substance related disorders and attended either the outpatients and inpatient services of Neuropsychiatry Department and Center of Psychiatry, Neurology, and Neurosurgery hospital at Tanta University or Andrology unite of Urology department at Tanta University Hospital. After ethical approval from Tanta University Institutional Review Board, a written informed consent was obtained from each participant.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Kupelian V, Araujo AB, Chiu GR, Rosen RC, McKinlay JB. Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. *Prev Med.* 2010;50:19-25.
2. Kamel M, Ghanem M, El Mahalawy N, Saad A, Asaad T, Mansour M, et al. Characteristics of patients attending the Substance Abuse Unit in the Institute of Psychiatry, Ain Shams University. *MECP.* 1995;2:184-91.
3. El-Sawy H, Abd Elhay M. Characteristics of substance dependence in adolescents with and without a history of trauma. *MECP.* 2011;18:211–6.
4. Wu T, Yue X, Duan X, Luo D, Cheng Y, Tian Y, et al. Efficacy and safety of tramadol for premature ejaculation: A systematic review and meta-analysis. *Urology.* 2012;80:618-24.
5. DeRogatis L, Burnett A. Key Methodological Issues in Sexual Medicine Research. *JSM.* 2007;4:527–37.
6. Eskandarieh S, Nikfarjam A, Tarjoman T, Nasehi A, Jafari F, Saberi-Zafarghandi MB. Descriptive aspects of injection drug users in Iran's national harm reduction program by methadone maintenance treatment. *Iran J Public Health.* 2013;42:588-93.
7. Bhavsar V, Bhugra D. Cultural factors and sexual dysfunction in clinical practice. *Adv Psychiatr Treat.* 2013;19:144-52.
8. El-Hadidy MA, El-Gilany A-H. Physical and sexual well-being during and after tramadol dependence. *Middle East Curr Psychiatry.* 2014;21:148-51.
9. Hassan MA, Sidik MT, Naem MMA, Abd El-Maseeh SAS. Sexual dysfunctions among male patients with tramadol abuse. *MJMR.* 2019;30 73-9.
10. Meena PK, Vohra A, Rajput R. Prevalence and pattern of alcohol and substance abuse in urban areas of Rohtak city. *Indian J Psychiatry.* 2002;44:348.
11. Lambert D, Gale JA, Hartley D. Substance abuse by youth and young adults in rural America. *J Rural Health.* 2008;24:221-8.
12. Kimani J, Tumuti S, Ndambuki P. Relationship between levels of exposure to mass media and students drug abuse in selected secondary schools in nakuru county, kenya. *J humanit soc sci.* 2020;1:43-52.
13. O'Farrell TJ, Fals-Stewart W. Behavioral couples therapy for alcoholism and drug abuse. *J Subst Abuse Treat.* 2000;18: 51-4.
14. Rotermann M. Analysis of trends in the prevalence of cannabis use and related metrics in Canada. *Health Rep.* 2019;30:3-13.
15. Banks DE, Zapolski TCB. Impulsivity and problem drinking in college: Examining the mediating role of sex-related alcohol

- expectancies and alcohol use at sex. *Subst Use Misuse*. 2017;52:992-1002.
16. Celio MA, MacKillop J, Caswell AJ, Mastroleo NR, Kahler CW, Barnett NP, et al. Interactive relationships between sex-related alcohol expectancies and delay discounting on risky sex. *Alcohol Clin Exp Res*. 2016;40:638-46.
  17. Messman-Moore TL, Ward RM, DeNardi KA. The impact of sexual enhancement alcohol expectancies and risky behavior on alcohol-involved rape among college women. *Violence Against Women*. 2013;19:449-64.
  18. Nash SD, Katamba A, Mafigiri DK, Mbulaiteye SM, Sethi AK. Sex-related alcohol expectancies and high-risk sexual behaviour among drinking adults in Kampala, Uganda. *Glob Public Health*. 2016;11:449-62.
  19. Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardò FP. When "chems" meet sex: A rising phenomenon called "chemsex". *Curr Neuropharmacol*. 2017;15:762-70.
  20. Legha R, Raleigh-Cohn A, Fickenscher A, Novins D. Challenges to providing quality substance abuse treatment services for American Indian and Alaska native communities: perspectives of staff from 18 treatment centers. *BMC psychiatry*. 2014 ;14:1-10.
  21. Behrendt S, Wittchen HU, Höfler M, Lieb R, Beesdo K. Transitions from first substance use to substance use disorders in adolescence: Is early onset associated with a rapid escalation? *Drug Alcohol Depend*. 2009;99:68-78.
  22. Okoli CTC, Richardson CG, Ratner PA, Johnson JL. Adolescents' self-defined tobacco use status, marijuana use, and tobacco dependence. *Addict Behav*. 2008;33:1491-9.
  23. Timberlake DS, Haberstick BC, Hopfer CJ, Bricker J, Sakai JT, Lessem JM, et al. Progression from marijuana use to daily smoking and nicotine dependence in a national sample of US adolescents. *Drug Alcohol Depend*. 2007;88:272-81.
  24. Richter KP, Ahluwalia HK, Mosier MC, Nazir N, Ahluwalia JS. A population-based study of cigarette smoking among illicit drug users in the United States. *Addiction*. 2002;97:861-9.
  25. La Pera G, Carderi A, Marianantoni Z, Lentini M, Taggi F. The role of sexual dysfunctions in inducing the use of drug in young males. *Arch Ital Urol Androl*. 2006 ;78:101-6.
  26. Tubman JG, Gil AG, Wagner EF, Artigues H. Patterns of sexual risk behaviors and psychiatric disorders in a community sample of young adults. *J Behav Med*. 2003;26:473-500.
  27. O'Hare T. Risky sex and drinking contexts in freshman first offenders. *Addictive Behaviors*. 2005;30:585-8.
  28. Refaat A. Practice and awareness of health risk behaviour among Egyptian university students. *EMHJ*. 2004;10:72-81.
  29. Nada KH, El Daw AS. Violence, abuse, alcohol and drug use, and sexual behaviors in street children of Greater Cairo and Alexandria, Egypt. *Aids*. 2010 ;24:S39-S44.
  30. Chikoko M. Masturbation and substance abuse among street children of harare central business district, Zimbabwe. *Journal of Interdisciplinary Academic Research (JIAR) ISSN*. 2617:2976.
  31. Angulo J, Assar M, Martínez-Salamanca J, Fuente JM, Fernández A, Sánchez-Ferrer A, et al. 213 Nrf2 activation improves both hyperpolarization- and NO-mediated responses in penile vasculature from patients with erectile dysfunction. *J Sex Med*. 2018;15:S205-S6.
  32. Xu JJ, Zhang C, Hu QH, Chu ZX, Zhang J, Li YZ, et al. Recreational drug use and risks of HIV and sexually transmitted infections among Chinese men who have sex with men: Mediation through multiple sexual partnerships. *BMC Infect Dis*. 2014;14:642.
  33. Abdelazim S, Abolmagd S, Abdalla H, Enaba D, Elsheikh S, Moselhy H. Sexual dysfunction and sex hormone levels in egyptian opioid- dependent males. 2015 ;33:2321-3647.
  34. Cushman P. Plasma testosterone in narcotic addiction. *Am J Med*. 1973 ;55:452-8.
  35. Al-Gommer O, George S, Haque S, Moselhy H, Saravanappa T. Sexual dysfunctions in male opiate users: A comparative study of heroin, Methadone, and Buprenorphine. *Addictive Disorders & Their Treatment*. 2007;6:137-43.
  36. Abd El-Qader M, El-Rasheed A, Ismail G, Awaad M, El-Habiby M, Ibrahim N. Sexual dysfunction in opiate use disorder in male Egyptian patients. M Sc degree thesis, Faculty of Medicine, Ain Shams University; 2017.

37. Palha AP, Esteves M. A study of the sexuality of opiate addicts. *Journal of Sex & Marital Therapy*. 2002;28:427-37.
38. Babakhanian M, Mehrgerdi ZA, Shenaiy Y. Sexual dysfunction in male crystalline heroin dependents before and after MMT: A pilot study. *Archives of Iranian medicine*. 2012;15:0-.
39. Abel EL. Marijuana and sex: A critical survey. *Drug and Alcohol Dependence*. 1981;8:1-22.
40. Chopra GS, Jandu BS. Psychoclinical effects of long-term marijuana use in 275 Indian chronic users. A comparative assessment of effects in Indian and USA users. *Annals of the New York Academy of Sciences*. 1976;282:95-108.
41. Koff WC. Marijuana and sexual activity. *Journal of Sex Research*. 1974;10:194-204.
42. Goldsmith D, Hunt D, Lipton D, Strug D. Methadone folklore: Beliefs about side effects and their impact on treatment. *Human Organization*. 1984;43:330-40.
43. Aversa A, Rossi F, Francomano D, Bruzziches R, Bertone C, Santemma V, et al. Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. *Int J Impot Res*. 2008;20:566-73.
44. Kumsar N, Kumsar Ş, Dilbaz N. Sexual dysfunction in men diagnosed as substance use disorder. *Andrologia*. 2016;48:1229-35.
45. Kumsar NA, Kumsar Ş, Dilbaz N. Sexual dysfunction in men diagnosed as substance use disorder. *Andrologia*. 2016;48:1229-35.
46. Drobnis EZ, Nangia AK. Pain medications and male reproduction. *Impacts of Medications on Male Fertility*: Springer; 2017;39-57.
47. Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. *Pharmacol Biochem Behav*. 1986;24:1749-54.
48. Mukhtar AH, Elbagir NM, Gubara AA. Sex hormones levels as influenced by cannabis sativa in rats and men. *Pak J Nutr*; 2012.
49. Gorzalka BB, Hill MN, Chang SC. Male–female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. *Hormones and behavior*. 2010;58:91-9.
50. Wu LT, Ling W, Burchett B, Blazer DG, Shostak J, Woody GE. Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: Results from the National Drug Abuse Treatment Clinical Trials Network. *Substance Abuse and Rehabilitation*. 2010;1:13.

© 2021 Tolba et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle4.com/review-history/71947>